进口与国产培美曲塞二钠联合顺铂一线治疗非小细胞肺癌成本效果分析  

Cost effectiveness analysis of abroad and domestic pemetrexed disodium combined with cisplatin as first-line treatment in non-small cell lung cancer

作　　者：栾伟[1] 郭绍来[1] 徐艳萍[1] 

机构地区：[1]解放军总医院药品保障中心,北京100853

出　　处：《中国医药》2012年第5期563-564,共2页China Medicine

摘　　要：目的 对进口与国产培美曲塞二钠联合顺铂一线治疗非小细胞肺癌（NSCLC）进行成本效果分析.方法 筛选2009年9月至2011年7月我院应用培美曲塞二钠联合顺铂一线治疗NSCLC患者60例,按化疗方案中选用培美曲塞二钠的不同将60例患者分为进口药组（应用进口培美曲塞二钠,32例）和国产药组（应用国产培美曲塞二钠,28例）,运用药物经济学成本-效果分析方法进行研究.结果 进口药组与国产药组有效率分别为43.7％ （14/32）和32.1％ （9/28）,差异有统计学意义（P＜0.05）；成本效果比分别为892.4、724.2,差异无统计学意义（P＞0.05）.结论 国产培美曲塞二钠更具成本效果性,但与进口培美曲塞二钠相比,疗效尚需提高.Objective To analyze the cost effectiveness of abroad and domestic pemetrexed combined with cisplatin as first-line treatment in non-small cell lung cancer （NSCLC）. Methods From September 2009 to July 2011, 60 patients of NSCLC who were treated with pemetrexed combined with cisplatin as first-line treatment in our hospital were enrolled. Among these patients, 32 ones had abroad pemetrexed disodium and 28 ones were domestic pemetrexed disodium. The cost effectiveness analysis of pharmacoeconomics was analyzed. Results The effectiveness of the two groups was 43.7% （ 14/32 ） and 32.1% （9/28）. The ratio of cost effectiveness of the two groups was 892.40 and 724.20 respectively. Conclusion Domestic pemetrexed disodium has cost effectiveness. But compared with abroad pemetrexed disodium, domestic pemetrexed disodium has lower clinical effectiveness.

关 键 词：癌 非小细胞肺 成本及成本分析 成本-效果分析 培美曲塞二钠 

分 类 号：R956[医药卫生—药学]